Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand the real-world effectiveness against severe coronavirus disease 2019 (COVID-19) and among people at increased risk for poor outcomes. Methods: In a multicenter case-control analysis of US adults hospitalized March 11–May 5, 2021, we evaluated vaccine effectiveness to prevent COVID-19 hospitalizations by comparing odds of prior vaccination with a messenger RNA (mRNA) vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with COVID-19 and hospital-based controls who tested negative for SARS-CoV-2. Results: Among 1212 participants, including 593 cases and 619 controls, median age was 58 years, 22.8% were Black, 13.9% were Hispanic, and 21.0% had immunosuppression. SARS-CoV-2 lineage B0.1.1.7 (Alpha) was the most common variant (67.9% of viruses with lineage determined). Full vaccination (receipt of 2 vaccine doses ≥14 days before illness onset) had been received by 8.2% of cases and 36.4% of controls. Overall vaccine effectiveness was 87.1% (95% confidence interval [CI], 80.7–91.3). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18–49 years (97.4%; 95% CI, 79.3–9.7). Among 45 patients with vaccine-breakthrough COVID hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (62.9%; 95% CI,20.8–82.6) than without immunosuppression (91.3%; 95% CI, 85.6–94.8). Conclusion: During March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing COVID-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 5×
“We conducted a prospective observational case-control evaluation of vaccine effectiveness by comparing the odds of antecedent SARS-CoV-2 vaccination in hospitalized case-patients with Covid19 versus control-patients without Covid-19.”
BackgroundResultInfluentialEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“During implementation of the national SARS-CoV-2 vaccination program in Israel between December 2020 and February 2021, the Pfizer BioNTech vaccine product demonstrated 87% vaccine effectiveness for the prevention of Covid-19 hospitalizations with a mean follow-up of 15 days.[27] Results of our US analysis in a popula…”
MethodGarg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335 · cited 1×
“In this analysis, we evaluated the effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations by vaccine product, by age group, and by underlying medical conditions.[5]”
MethodSelf-citationAntibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Boyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik-Wang, J. M. (2021) · JAMA · doi:10.1001/jama.2021.7489 · Cited by 955
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
Self-citationRoth, G. A., Emmons-Bell, S., Alger, H. M., Bradley, S. M., Das, S. R., de Lemos, J. A., Gakidou, E., Elkind, M. S. V., Hay, S., Hall, J. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8828 · Cited by 145
Research works printed but not linked: 13
- Grijalva, 2021, Influenza vaccine effectiveness for prevention of severe influenza-associated illness among adults in the United States, 2019-2020: a test-negative study, Clin Infect Dis, 10.1093/cid/ciab462 · DOI
- Tenforde, 2020, Influenza vaccine effectiveness against hospitalization in the United States, 2019-2020, J Infect Dis
- Ferdinands, 2019, Prevention of influenza hospitalization among adults in the United States, 2015-2016: results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN), J Infect Dis, 220, 1265, 10.1093/infdis/jiy723 · DOI
- Foppa, 2013, The case test-negative design for studies of the effectiveness of influenza vaccine, Vaccine, 31, 3104, 10.1016/j.vaccine.2013.04.026 · DOI · Paper page
- Tenforde, 2021, Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years - United States, January-March 2021, MMWR Morb Mortal Wkly Rep, 70, 674, 10.15585/mmwr.mm7018e1 · DOI · Paper page
- Feldstein, 2021, Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates, J Infect Dis, 10.1093/infdis/jiab273 · DOI
- Feldstein, 2021, Incorporating real-time influenza detection into the test-negative design for estimating influenza vaccine effectiveness: the Real-time Test-negative Design (rtTND), Clin Infect Dis, 72, 1669, 10.1093/cid/ciaa1453 · DOI
- Jackson, 2017, Influenza vaccine effectiveness in the United States during the 2015-2016 season, N Engl J Med, 377, 534, 10.1056/NEJMoa1700153 · DOI · Paper page
- Durand, 2013, Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study, PLoS One, 8, e71079, 10.1371/journal.pone.0071079 · DOI · Paper page
- Pilishvili, 2021, Interim estimates of vaccine effectiveness of Pfizer-Biontech and Moderna COVID-19 vaccines among health care personnel - 33 U.S. sites, January-March 2021, MMWR Morb Mortal Wkly Rep, 70, 753, 10.15585/mmwr.mm7020e2 · DOI · Paper page
- Ruddy, 2021, High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases, Ann Rheum Dis, 10.1136/annrheumdis-2021-220656 · DOI
- Patel, 2020, Analysis of marketscan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States, Emerg Infect Dis, 26, 1720, 10.3201/eid2608.191493 · DOI
- Hollis, 2021, Racial and ethnic disparities in incidence of SARS-CoV-2 infection, 22 US states and DC, January 1-October 1, 2020, Emerg Infect Dis, 27, 1477, 10.3201/eid2705.204523 · DOI
Cited by
Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069761 · Cited by 656
Self-citationEfficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
Tenforde, M. W., Self, W. H., Adams, K., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2021) · JAMA · doi:10.1001/jama.2021.19499 · Cited by 633
Self-citationSelf, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7038e1 · Cited by 406
Self-citationZambrano, L. D., Newhams, M. M., Olson, S. M., Halasa, N. B., Price, A. M., Boom, J. A., Sahni, L. C., Kamidani, S., Tarquinio, K. M., Maddux, A. B., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7102e1 · Cited by 279
Self-citation
Metadata
- Authors
- Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Exline, M. C., Gong, M. N., Mohamed, A., Henning, D. J., Steingrub, J. S., Peltan, I. D., Brown, S. M., Martin, E. T., Monto, A. S., Khan, A., Hough, C. L., Busse, L. W., ten Lohuis, C. C., Duggal, A., Wilson, J. G., Gordon, A. J., Qadir, N., Chang, S. Y., Mallow, C., Gershengorn, H. B., Babcock, H. M., Kwon, J. H., Halasa, N., Chappell, J. D., Lauring, A. S., Grijalva, C. G., Rice, T. W., Jones, I. D., Stubblefield, W. B., Baughman, A., Womack, K. N., Lindsell, C. J., Hart, K. W., Zhu, Y., Olson, S. M., Stephenson, M., Schrag, S. J., Kobayashi, M., Verani, J. R., Self, W. H., & Influenza and Other Viruses in the Acutely Ill (IVY) Network
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-06
- Volume
- 74
- Issue
- 9
- Pages
- 1515-1524
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3187850115
- Cited by
- 149
- References
- 11
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- US Centers for Disease Control and Prevention (75D30121F00002)
- Clinical and Translational Science (UL1 TR002243)
- National Institute of Allergy And Infectious Diseases, National Institutes of Health (1K23AI137321)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. https://app.cochat.ai/papers/10.1093/cid/ciab687
- The paper
- Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Exline, M. C., . . . Influenza and Other Viruses in the Acutely Ill (IVY) Network. (2022). Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab687
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.